$6.80
3.13% yesterday
Nasdaq, Nov 15, 10:00 pm CET
ISIN
US56400P7069
Symbol
MNKD
Sector
Industry

MannKind Corporation Stock price

$6.80
+0.19 2.87% 1M
+2.35 52.81% 6M
+3.16 86.81% YTD
+3.05 81.33% 1Y
+2.01 41.96% 3Y
+5.61 469.04% 5Y
-24.50 78.27% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-0.22 3.13%
ISIN
US56400P7069
Symbol
MNKD
Sector
Industry

Key metrics

Market capitalization $1.88b
Enterprise Value $1.97b
P/E (TTM) P/E ratio 96.73
EV/FCF (TTM) EV/FCF 69.06
EV/Sales (TTM) EV/Sales 7.38
P/S ratio (TTM) P/S ratio 7.02
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 51.35%
Revenue (TTM) Revenue $267.20m
EBIT (operating result TTM) EBIT $57.25m
Free Cash Flow (TTM) Free Cash Flow $28.54m
Cash position $251.59m
EPS (TTM) EPS $0.07
P/E forward 68.82
P/S forward 6.85
EV/Sales forward 7.19
Short interest 15.74%
Show more

Is MannKind Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

MannKind Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a MannKind Corporation forecast:

4x Buy
80%
1x Hold
20%

Analyst Opinions

5 Analysts have issued a MannKind Corporation forecast:

Buy
80%
Hold
20%

Financial data from MannKind Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
267 267
51% 51%
100%
- Direct Costs 75 75
23% 23%
28%
192 192
66% 66%
72%
- Selling and Administrative Expenses 83 83
8% 8%
31%
- Research and Development Expense 44 44
51% 51%
16%
65 65
1,827% 1,827%
24%
- Depreciation and Amortization 7.86 7.86
41% 41%
3%
EBIT (Operating Income) EBIT 57 57
712% 712%
21%
Net Profit 22 22
169% 169%
8%

In millions USD.

Don't miss a Thing! We will send you all news about MannKind Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

MannKind Corporation Stock News

Neutral
Seeking Alpha
8 days ago
MannKind Corporation (NASDAQ:MNKD ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Michael Castagna - CEO Chris Prentiss - CFO Conference Call Participants Andreas Argyrides - Oppenheimer Olivia Brayer - Cantor Fitzgerald Faisal Khurshid - Leerink Partners Anish Nikhanj - RBC Capital Markets Brandon Folkes - Rodman & Renshaw Operator Good afternoon, and welcom...
Neutral
GlobeNewsWire
8 days ago
Conference Call to Begin Today at 4:30 p.m. (ET) 3Q 2024 Total revenues of $70M; +37% vs.
Neutral
GlobeNewsWire
10 days ago
DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
More MannKind Corporation News

Company Profile

MannKind Corp. is a biopharmaceutical company. It focuses on the discovery, development and, commercialization of therapeutic products for diseases, such as diabetes and cancer. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Westlake Village, CA.

Head office United States
CEO Michael Castagna
Employees 414
Founded 1991
Website www.mannkindcorp.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today